{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "AMN",
  "name": "AMN Healthcare Services",
  "url": "https://frontierpicks.com/dossiers/AMN/",
  "json_url": "https://frontierpicks.com/dossiers/AMN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Healthcare-staffing cyclical recovery, real but maturing and now at the highs: ~$32.9 (2026-07-24), just off a fresh 52-wk high $36.27 (~+120% off $14.87). Truist's 2026-07-22 lift to a Street-high $40 Buy is the first target leading price, but the broad Street stays Hold ~$25-30 and the binary 2026-08-06 Q2 print — guide already below consensus — is the swing. Paying up into it is an extended entry.",
  "invalidation_trigger": "A weekly close below $28 breaks the July higher-low base and the rising trend carrying the recovery leg; a close beneath the $26 May breakout shelf resets it to a failed-recovery value trap. Secondary: the 2026-08-06 print guiding Q3 revenue under the ~$630M run-rate, or Jefferies temp-nurse demand negative 3+ straight weeks.",
  "catalyst_date": null,
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-07-02",
  "invalidation_fired": false,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Aggregator feeds garble AMN figures (old $70-88 and $34-47 target marks, $1.378B/$3.42B revenue lines). Anchor on the reported ~$620-675M quarterly run-rate.",
    "Reported results include lumpy labor-disruption billing accruals; Q2 2026 carried ~$27M of revenue and ~290bps of gross margin from non-recurring items.",
    "Three reporting segments: Nurse & Allied, Physician & Leadership, Technology & Workforce. Only Nurse & Allied is guided to grow in Q3 2026.",
    "Cross Country Healthcare (CCRN) is being taken private by Knox Lane, removing the cleanest listed pure-play comp for travel-nurse demand.",
    "Headline valuation screens run on adjusted EPS; GAAP results have been loss-making through the recovery, so trailing P/E screens read as blank or distorted."
  ],
  "body_markdown": "\n> NOTE — This is a refresh of coverage first opened 2026-05-10. The prior note's binary (the 2026-08-06 Q2 print) has resolved; the frame below advances from it.\n\n## AMN — AMN Healthcare Services, Inc.\n\n## Current Thesis\nThe binary that dominated the last note resolved in the bulls' favour. Q2 2026, reported 2026-08-06 after the close, put revenue at $673.2M against $628.4M consensus and adjusted EPS at $0.77 against $0.19 — revenue landed 6% above the high end of the company's own guidance, and gross margin came in at 30.6%, 210bps above the top of the guided range. Management then guided Q3 to $640–655M versus $618.2M consensus, the first guide of this cycle to sit above the Street rather than under it. Four target revisions followed inside 23 days: Truist $40 (2026-07-22), UBS to $35 from $32 and Baird to $36 from $26 (both 2026-08-07), Citizens to $40 (2026-08-14). The upgrade cluster the earlier coverage set as the re-acceleration condition arrived.\n\nWhat keeps this maturing rather than accelerating is the quality of the beat and the tape's answer to it. Roughly $27M of Q2 revenue and about 290bps of the gross-margin expansion came from non-recurring labor-disruption billing accruals and reserve adjustments (Q2 2026 call, 2026-08-06). The Q3 segment guide has Nurse & Allied +9–11% YoY carrying the whole load while Physician & Leadership is guided -5 to -7% and Technology & Workforce -11 to -13%. And a beat of that magnitude extended the 52-week high only to $36.60, from the $36.27 registered before the print; the 2026-08-14 close was $34.50, 5.7% under it, with RSI(14) at 53. Good news was absorbed, not chased.\n\n## Bull Case\n- Q2 2026 (2026-08-06): revenue $673.2M vs $628.4M consensus, adjusted EPS $0.77 vs $0.19 estimate, revenue 6% above the high end of guidance. The prior guide of $620–635M had been *below* the then-consensus $634.9M; the actual print cleared both.\n- Q3 2026 guide $640–655M against $618.2M consensus (2026-08-06) — a guide-up of that shape is the first quantitative evidence in this cycle that demand, not cost-out, is doing the work.\n- Nurse & Allied Solutions guided +9–11% YoY for Q3 (2026-08-06 call) — the largest segment returning to high-single-digit growth after two years of bill-rate deflation.\n- Sell-side marks now lead price: $35 UBS (2026-08-07), $36 Baird (2026-08-07), $40 Truist (2026-07-22), $40 Citizens Market Outperform (2026-08-14), all above the 2026-08-14 close of $34.50. BMO maintained Buy 2026-08-08.\n- Gross margin 30.6% in Q2, +80bps YoY (2026-08-06) — well above the 28–28.5% the company had guided for the quarter, even before separating the non-recurring contribution.\n- Mix-shift optionality persists: AMN Language Services acquired Jaide Health on 2026-06-09, adding AI-enabled medical interpretation to a business the market still prices as cyclical staffing.\n\n## Bear Case\n- The headline beat is not clean. Approximately $27M of revenue and ~290bps of gross margin in Q2 came from non-recurring labor-disruption billing accruals and reserve adjustments (2026-08-06 call). Strike-driven revenue is lumpy and does not annualise.\n- Two of three segments are guided to shrink in Q3: Physician & Leadership -5 to -7% YoY, Technology & Workforce -11 to -13% (2026-08-06). The tech line is the higher-margin, recurring piece the mix-shift story leans on.\n- Adjusted EBITDA margin is guided 6.5–7.0% for Q3, versus the 6.7–7.2% band guided for Q2 — the margin guide steps down even as revenue steps up.\n- Ratings did not move with the targets. UBS remains Neutral at $35; Baird's raise to $36 came without a rating change. Higher numbers inside unchanged ratings is a different signal from a re-rating.\n- Price did not confirm. The beat produced a 52-week high of only $36.60 against $36.27 pre-print, and the 2026-08-14 close of $34.50 sits 5.7% below it — eight sessions of no follow-through after a 6%-above-guidance quarter.\n- The comp set is thinning: Cross Country Healthcare's take-private by Knox Lane at $13.25/share (~$437M, announced 2026-05-06) is targeted to close ~Q3 2026, removing the cleanest listed pure-play read on travel-nurse demand.\n\n## Setup & Price Structure\nReference close 2026-08-14: $34.50. 52-week high $36.60, distance -5.7%. Three-month return +20.6%. RSI(14) 53 — mid-range, with the advance flattening rather than extending.\n\nThe structure to watch is the post-print shelf. Price traded near $32.89 on 2026-07-24, gapped up on the 2026-08-06 beat, made $36.60, and has spent the sessions since between that high and the pre-print zone. That leaves two observable boundaries: $36.60 above, where a weekly close would argue the narrative has flipped to accelerating; and roughly $31 below, where a weekly close would give back the entire post-print advance and put the tape back inside the July range that existed before the guide-up.\n\nCrowding and positioning observables, stated as observables: four sell-side target revisions between 2026-07-22 and 2026-08-14, all upward, all now above spot — attention is expanding, and the marks no longer lag the price. The name appeared in retail-facing aggregation coverage on 2026-08-06 (\"12 Health Care Stocks Moving In Thursday's After-Market Session\"). No insider transactions appear in the filing feed through 2026-08-14. No earnings date falls inside the next 30 days, so the next scheduled company-specific test is roughly three months out.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-04 (est.)** — BLS Employment Situation for August, healthcare payrolls line. Hospital hiring appetite is the upstream driver of contract-labor budgets.\n- **Weekly, through 2026-09-15** — Jefferies temp-nursing demand series. With CCRN going private this is the main high-frequency sector read; three-plus consecutive negative weeks would contradict the Q3 Nurse & Allied +9–11% guide.\n- **~2026-09-30 (est.)** — targeted close of the Knox Lane / Cross Country Healthcare take-private at $13.25/share, announced 2026-05-06.\n- **~2026-11-05 (est.)** — Q3 2026 print. The first quarter that has to clear $640–655M without the ~$27M non-recurring benefit that flattered Q2.\n\n## Elapsed catalysts\n\n- **Early September** — healthcare conference season (Morgan Stanley, Baird, Wells Fargo). AMN participation is not confirmed on the company's public events calendar as of 2026-08-16; treat as unscheduled until it posts. *(passed 10d ago)*\n\n## What Would Change Our Mind\nThe structural break is the loss of the post-print shelf. A weekly close below $31 erases the entire move the 2026-08-06 beat-and-raise produced and returns price into the July range, which would say the market has decided the guide-up was funded by items that do not repeat. Below that, a close beneath the $26 May breakout shelf resets the whole recovery leg to a failed cyclical.\n\nOn fundamentals: Q3 revenue landing at or under the $640M low end at the ~November print, or Nurse & Allied growth coming in below the guided +9–11%, would break the demand-inflection leg specifically — that segment is the only one guided to grow. A further step-down in adjusted EBITDA margin guidance below the 6.5–7.0% band would say the margin recovery was reserve-driven.\n\nOn positioning: the sell-side cluster is target raises inside unchanged ratings. If the next 30 days pass with no rating change to Buy or Outperform from a Neutral house, the $40 marks stay outliers rather than a consensus reset, and the theme drifts toward saturated — mainstream marks already above spot with no fresh incremental bid.\n\nUpside flip: a weekly close above $36.60 on continued guide-ups would move the label to accelerating and make the current mid-range action a base rather than a stall.\n\n## Correlation Notes\n- **Inverse to hospital operators' cost line.** AMN revenue is HCA, Tenet and Community Health's contract-labor expense. Hospital commentary about \"normalising labor costs\" is negative for AMN's bill rates; the two do not trade together on the same news.\n- **Labor disruption is a revenue driver, not just a headline.** The ~$27M non-recurring item in Q2 traces to strike-related billing accruals — nurse union action is idiosyncratic upside that also makes quarterly comparisons unreliable.\n- **Peer comp is disappearing.** Cross Country (CCRN) exits public markets on the Knox Lane close targeted ~Q3 2026. What remains as read-across is generalist staffing (Robert Half, ManpowerGroup, Kelly), which tracks white-collar hiring rather than clinical labor — a weak proxy.\n- **Small-cap beta.** At roughly $1.3B market capitalisation the name carries Russell-2000 flow sensitivity that has nothing to do with nurse demand.\n- **Segment divergence within the name.** Technology & Workforce Solutions is guided -11 to -13% for Q3 while Nurse & Allied is +9–11%; the consolidated line hides two businesses moving in opposite directions, and aggregator \"revenue growth\" screens will read the blend.",
  "first_seen": "2026-05-10",
  "last_analyzed": "2026-08-16T13:56:19+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}